Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label, Randomized, Controlled, Dose Cohort, Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
Conditions
Interventions
Standard of Care with Lofexidine
Standard of Care without Lofexidine
Locations
1
United States
Marshall Health
Huntington, West Virginia, United States
Start Date
October 2, 2023
Primary Completion Date
May 11, 2025
Completion Date
October 1, 2026
Last Updated
October 1, 2025
Lead Sponsor
BioCorRx Pharmaceuticals Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions